Incoming FDA Center for Tobacco Products director Mitch Zeller starts March 4. Zeller is currently senior VP at Pinney Associates, a science and public health policy consulting firm in Bethesda, Md. Prior to joining Pinney, Zeller was executive VP of the American Legacy Foundation, then associate commissioner and director of the FDA’s Office of Tobacco Programs, where he built the first nationwide program to reduce youth access to tobacco in the late 1990s before a Supreme Court decision shut down that office. He also served as a U.S. delegate to the World Health Organization Working Group for the Framework Convention on Tobacco Control. Zeller began his public health career as assistant director for legal affairs at the Center for Science in the Public Interest. Following a nicotine replacement therapy public hearing in January, Zeller said FDA is at a crossroads and the U.S. has been lapped by other countries in allowing NRT indications like “reduce to quit” or “extended duration of use.” NRT issues fall under the purview of the agency’s drug center, not CTP ([A#05130114002]). Zeller replaces Lawrence Deyton, who is becoming a clinical professor of medicine and health policy at the George Washington University School of Medicine and Health Sciences.
In Brief
Zeller heads FDA tobacco center; FDA denies P&G diabetes claim; Meda depends on OTCs; Ocean Nutrition boosts DSM; Elcelyx innovates in financing round; FDA warns DMAA firm on GMP violations; probiotics get Canadian claim approval.
More from Compliance
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
Results from a single-arm study cannot support representations on overall survival, progression-free survival and disease control rate for the cancer drug, the Office of Prescription Drug Promotion said in another “untitled” letter implicating the agency’s CFL guidance.
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
More from Pink Sheet
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.